Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 913-919

  Pinto, António E ^a   Silva, Giovani ^b   Banito, Ana ^a   Leite, Valeriano ^a   Soares, Jorge ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Anaplastic thyroid carcinoma; DNA ploidy; Poorly differentiated thyroid carcinoma; Prognosis; RAS mutations; S phase fraction

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; IODINE 131; RAS PROTEIN;

ADULT; ANAPLASTIC THYROID CARCINOMA; ANEUPLOIDY; ARTICLE; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; FROZEN SECTION; HUMAN; HUMAN TISSUE; MALE; MITOSIS RATE; OVERALL SURVIVAL; PLOIDY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; SEX DIFFERENCE; THYROID CARCINOMA; THYROIDECTOMY; TUMOR DIFFERENTIATION;

ADULT; AGED; ANEUPLOIDY; BIOLOGICAL MARKERS; CARCINOMA; FEMALE; FLOW CYTOMETRY; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; S PHASE; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 54949150226     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000091     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal TG and Thun MJ: Cancer statistics. CA Cancer J Clin 56: 106-130, 2006.
2. Gilliland FD, Hunt WC, Morris DM and Key CR: Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79: 564-573, 1997.
3. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A national cancer data base report on 53,856 cases of thyroid carcinoma-treated in the U.S., 1985-1995. Cancer 83: 2638-2648, 1998.
4. Nishida T, Katayama S, Tsujimoto M, Nakamura J and Matsuda H: Clinicopathological significance of poorly differentiated thyroid carcinoma. Am J Surg Pathol 23: 205-211, 1999.
5. Are C and Shaha AR: Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13: 453-464, 2006.
6. Lang BH and Lo CY: Surgical options in undifferentiated thyroid carcinoma. World J Surg 31: 969-977, 2007.
7. Brignardello E, Gallo M, Baldi I, Palestini N, Piovesan A, Grossi E, Ciccone G and Boccuzi G: Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 156: 425-430, 2007.
8. Zbieranowski I and Murray D: The study of endocrine tumors by flow and image cytometry. Endocr Pathol 3: 63-82, 1992.
9. Pasieka JL, Zedenius J, Auer G, Grimelius L, Hoog A, Lundell G, Wallin G and Backdahl M: Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 112: 1154-1159, 1992.
10. Hrafnkelsson J, Stal O, Enestrom S, Jonasson JG, Bjornsson J, Olafsdottir K and Nordenskjold B: Cellular DNA pattern, S-phase frequency and survival in papillary thyroid cancer. Acta Oncol 27: 329-333, 1988.
11. Schroder S, Bocker W, Baisch H, Burk CG, Arps H, Meiners I, Kastendieck H, Heitz PU and Kloppel G: Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 61: 806-816, 1988.
12. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED and Wynford-Thomas D: Activated ras oncogenes in human thyroid cancers. Cancer Res 48: 4459-4463, 1988.
13. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ and Kaplan EL: N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 116: 1010-1016, 1994.
14. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J and Tallini G: Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21: 3226-3235, 2003.
15. Sobin LH and Wittekind CH (eds): International Union Against Cancer (UICC). TNM Classification of Malignant Tumours. 6th edition, Wiley-Liss, New York, 2002.
16. Deitch AD, Law H and White RD: A stable propidium iodide staining procedure for flow cytometry. J Histochem Cytochem 30: 967-972, 1982.
17. Sugg SL, Ezzat S, Rosen IB, Freeman JL and Asa SL: Distinct multiple RET/ PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83: 4116-4122, 1998.
18. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM and Santoro M: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623-1629, 2006.
19. Copland J,Á, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP and Smallridge RC: Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21 WAF1/ CIP1. Oncogene 25: 2304-2317, 2006.
20. Bravo SB, Garcia-Rendueles ME, Seoane R, Dosil V, Cameselle-Teijeiro J, Lopez-Lazaro L, Zalvide J, Barreiro F, Pombo CM and Alvarez CV: Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. Clin Cancer Res 11: 7664-7673, 2005.
21. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F and Schlumberger M: Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid 17: 639-646, 2007.
22. Klemi PJ, Joensuu H and Eerola E: DNA aneuploidy in anaplastic carcinoma of the thyroid gland. Am J Clin Pathol 89: 154-159, 1988.
23. Schelfhout LJ, Cornelisse CJ, Goslings BM, Hamming JF, Kuipers-Dijkshoom NJ, van de Velde CJ and Fleuren GJ: Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms. Int J Cancer 45: 16-20, 1990.
24. Salmon I, Gasperin P, Remmelink M, Rahier I, Rocmans P, Pasteels JL, Heimann R and Kiss R: Ploidy level and proliferative activity measurements in a series of 407 thyroid tumors or other pathologic conditions. Hum Pathol 24: 912-920, 1993.
25. Jónasson JG and Hrafnkelsson J: Nuclear DNA analysis and prognosis in carcinoma of the thyroid gland. A nationwide study in Iceland on carcinomas diagnosed 1955-1990. Virchows Archiv 425: 349-355, 1994.
26. DeLellis RA: Does the evaluation of proliferative activity predict malignancy of prognosis in endocrine tumors? Hum Pathol 26: 131-134, 1995.
27. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J and Lloyd RV: Expression of p27kipl and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 11: 169-174, 1998.
28. Soares P and Sobrinho-Simões M: Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Pathol Res Pract 191: 304-317, 1995.
29. Vasko V, Ferrand M, DiCristofaro J, Carayon P, Henry JF and de Micco C: Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88: 2745-2752, 2003.